메드팩토

235980KOSDAQ자연과학 및 공학 연구개발업

57.8 / 100

Reference Date: 2026-06-10

Financial Score22.5 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 33.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medfact is a biotech company established in 2013, specializing in the development of innovative drugs for refractory cancers using advanced genomic analysis technology. Its flagship product, Vactosertib, targets the TGF-β1 signaling pathway to modulate the tumor microenvironment and enhance the efficacy of existing cancer treatments when used in combination. The company is currently conducting clinical trials for various cancers, including colorectal, pancreatic, and osteosarcoma.

Number of Employees

54people

Average Salary

57.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

2.49Industry Average 3.244.0Point

In line with industry avg

ROE

-24.70Industry Average -32.093.5Point

Below industry avg

Debt Ratio

2.86Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

3.0 / 3

Avg ▲29.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.5% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
메드팩토, 신규 항암제 임상신청 앞두고 22개국 특허 출원
메드팩토의 차세대 항암제 후보물질 'MP010'에 대한 글로벌 특허 출원으로 기술 경쟁력 강화 및 시장 진출 기대감 상승.
Positive
메드팩토 ‘MP010’ 22개국 특허 출원…연내 임상 1상 IND 추...
메드팩토의 주요 항암제 파이프라인 MP010이 글로벌 제약사들과의 기술이전 논의를 통해 임상 1상 IND 신청을 앞두고 있어 긍정적인 시장 반응을 기대할 수 있다.
Positive
메드팩토 “항암 신약후보 글로벌 22개국 특허 출원…IND ‘막바지’...
메드팩토의 주요 항암제 후보물질 MP010에 대한 글로벌 특허 출원으로 신약 개발 진전 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,345Won52-week high 8,05052-week low 3,345

1-month return0.0Point

1m -32.97% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral대표이사변경2026-05-15
Neutral분기보고서 (2026.03)2026-05-13